Active Novo Growth Equity companies
|
Aerocrine is a medical technology company focused on improving the treatment of patients with inflamed airways. Measuring airways inflammation helps doctors to diagnose, monitor and optimise therapy for people with inflammatory airway diseases. The founders of Aerocrine emerged from the highly prestigious Karolinska Institute in Sweden where they were the first to identify nitric oxide (NO) as a marker of inflammation. Aerocrine has taken this significant discovery from laboratory to listed company and is now established in some of the world’s largest markets. The company markets two products globally NIOX Flex and NIOX MINO. Both are highly reliable and effective tools to assist in the diagnosis and control of airways disease. Novo A/S board representative: Scott Beardsley |
|||
|
|
|||
|
Archimedes Pharma is an international specialty pharmaceutical company focused on the oncology, pain, neurology, and critical care sectors. Archimedes Pharma is marketing an expanding portfolio of specialist products to hospital-based prescribers in Europe and the US and has established commercial organizations in the UK, US, France, Germany, Ireland, and Spain. Archimedes Pharma is growing its commercial presence through the acquisition of pharmaceutical companies and brands globally and through partnering with companies to drive sales of their innovative products. In parallel, Archimedes Pharma is also developing a robust, high-value pipeline of in-house products in pain, Parkinson's disease, and critical care. Novo A/S board representatives: Göran Ando and Ulrik Spork |
|||
|
|
|||
|
Orexo AB is a Swedish pharmaceutical company with a focus on the therapeutic areas of pain and inflammation. Orexo’s first proprietary developed drug, Abstral, for the treatment of breakthrough pain in cancer patients was launched in Europe in 2008. The second drug, Edluar - for the short-term treatment of insomnia was launched in the USA in 2009. Orexo has a number of projects in the pipeline and also markets two diagnostic products for the gastric ulcer bacteria, Helicobacter pylori, through its Kibion subsidiary. Novo A/S board representative: Michael Shalmi |
|||
|
|
|||